These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status? Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496 [TBL] [Abstract][Full Text] [Related]
5. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172 [TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
7. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Winston DJ; Busuttil RW Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129 [TBL] [Abstract][Full Text] [Related]
9. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
10. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. Reddy AJ; Zaas AK; Hanson KE; Palmer SM J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480 [TBL] [Abstract][Full Text] [Related]
11. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133 [TBL] [Abstract][Full Text] [Related]
12. Three-year experience with human cytomegalovirus infections in heart transplant recipients. Grossi P; Revello MG; Minoli L; Percivalle E; Zavattoni M; Poma G; Martinelli L; Gerna G J Heart Transplant; 1990; 9(6):712-9. PubMed ID: 2177498 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645 [TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Kelly JL; Albert RK; Wood DE; Raghu G Transplantation; 1995 Apr; 59(8):1144-7. PubMed ID: 7732561 [TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
18. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360 [TBL] [Abstract][Full Text] [Related]
19. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777 [TBL] [Abstract][Full Text] [Related]